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Protein-altering germline mutations implicate novel genes related to lung cancer 
development 
Abstract 
Germline mutations cause 3–10% of cancers diagnosed yearly1. Identifying cancer-related mutations can 
provide targets for personalized cancer screening, prevention2,3, treatment and drug development4. However, 
only a few germline mutations responsible for lung cancer etiology have been identified5. Here, by 
performing whole-exome analyses of mutations in two independent cohorts with 39,146 individuals of 
European ancestry and investigating gene expression levels in 7,773 samples, we found large-effect 
associations for lung adenocarcinoma with the L2307F mutation of ATM for lung cancer with a stop-gain 
mutation (Q4X) of a previously uncharacterized gene KIAA0930, which gene was found to be significantly 
over-expressed in lung cancer and most carcinomas in our study. All ATM-L2307F homozygotes had lung 
adenocarcinoma (P=0.004) and all KIAA0930-Q4X homozygotes had lung cancer (P=2.29x10-8). Despite 
being very rare in the general European population, L2307F was much more common in the Israeli 
population (MAF=0.023), especially in Ashkenazi Jews (47/640). L2307F was predicted to enhance ATM 
protein aggregation and is predicted to have a pathogenic effect on the ATM protein, but has not previously 
been associated with lung cancer or ataxia telangectasia. KIAA0930-Q4X completely abolishes KIAA0930 
transcription. Our results demonstrate ATM-L2307F and KIAA0930-Q4X increased lung cancer risk with 
large effects among heterozygotes and high risk for developing lung cancer among homozygotes indicating 
the importance of ATM and KIAA0930 for lung cancer etiology. Selected rare mutations in ATM have also 
been identified through the TCGA as associating with lung adenocarcinoma risk.  Individuals with 
mutations of ATM and KIAA0930 may benefit from targeted screening and the findings may suggest targets 
for treatment of lung cancer in selected patients. Our results offer novel genes to include in cancer panels 
for effective lung cancer screening and suggest new targets to advance our understanding of cancer 
pathogenesis.  
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Main 
Lung cancer is a leading cause of cancer death in the U.S. and around the world and represents a major 
public health problem6. Hereditary factors also play a crucial role in lung cancer etiology with an 
estimated 18% of lung cancer risk attributed to hereditary factors7. The first wave of genome-wide 
association studies identified susceptibility regions and common variants for lung cancer risk. However, 
few previous studies investigated the association between germline mutations and lung cancer risk 
because this type of research requires large sample sizes and high-coverage genome sequencing or large 
scale genotyping. Although only less than 1% of most populations are carriers of a germline mutation that 
drive cancers, these mutations may confer as much as an 80% lifetime risk for developing cancer8 and 
such mutations cause between 3–10% of cancers diagnosed yearly1. In addition, identification of cancer-
related mutations provided potential targets for cancer treatment and drug development.  The rare 
inherited T790M mutation of EGFR is associated with greatly increased risk for lung cancer in 
nonsmokers 9.  Individuals with this mutation do not respond well to first-line EGFR therapy 10 and a 
targeted approach to risk management and therapy is required for individuals carrying this mutation11. 
Similarly, identification of mutations in BRCA1 and BRCA2 led to the development of PARP inhibition 
therapy for breast cancer. Defining driver germline mutations for lung cancer may also help with targeted 
prevention and early detection, similar to the benefit conveyed in screening for harmful BRCA1 and 
BRCA2 germline mutations2,3.  Therefore, we investigated germline mutations with a large effect on lung 
cancer pathogenesis to offer insights into understanding cancer mechanisms. 
 
To discover driver germline mutations with high effect on lung cancer risk, we performed association 
analyses for all the mutations within the exome using a discovery cohort of 28,878 individuals of European 
ancestry (Supplementary Table 1). Three mutations, including rs56009889, rs150665432, and rs61816761 
had association P values of less than 5.0 x 10-8 and OR values of more than 2.0 in the discovery cohort 
(Supplementary Table 2).  
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We then validated these findings in an independent cohort consisting of 10,268 individuals of European 
ancestry, in which repeat genotyping was performed for 5742 subjects along with the discovery cohort to 
investigate the genotyping fidelity of the mutations for both cohorts. The variants rs56009889 and 
rs150665432 had excellent concordances of 99.95% and 99.08% for overall genotypes and 89.66% and 
92.31% for the rare alleles, respectively, which confirmed their genotyping fidelity in both cohorts. 
However, genotyping for rs61816761 showed poor concordance, so it was dropped from further analysis 
(Supplementary Table 3). Additionally, among unaffected individuals, the Minor Allele Frequencies 
(MAFs) of rs56009889 and rs150665432 in both cohorts were comparable to the MAFs found for European 
populations in the Exome Aggregation Consortium12, and were in agreement with MAFs in the NHLBI GO 
Exome Sequencing Project and the Trans-Omics for Precision Medicine Program13,14 (Supplementary 
Table 4), which supported the reliability of the genotyping data of  rs56009889 and rs150665432 in both 
cohorts. Therefore, we further investigated rs56009889 and rs150665432. 
 
Although rs56009889, mapping within ATM gene (Fig. 1a) is not reported as causing Ataxia 
Telangectasia15, its mutation results in L2307F missense mutation in the FAT domain which regulates ATM 
activity16 and thereby possibly affects its function (Supplementary Fig. 1a). Compared to non-carriers 
(C/C), L2307F carriers (T/C + T/T) had an increased risk of lung cancer with statistical significance in the 
discovery cohort (adjusted odds ratios (ORs)=4.19, P=3.56x10-7), though the increased risk did not reach 
significance in the replication cohort (Table 1). Among females, L2307F was significantly associated with 
lung cancer risk with ORs being 7.76 (P=0.0002) in the discovery cohort and 3.22 (P=0.03) in the 
replication cohorts. Among males, L2307F showed a weakly significant association with lung cancer risk 
in the discovery cohort and no association in the replication cohort (Fig. 2a and Supplementary Table 5). 
Stratification analysis by histology indicated that L2307F carriers had a significant 5.23-fold increased risk 
for lung adenocarcinoma (LAD) in the discovery cohort (P=6.47x10-9) and a 2.48-fold increased risk in the 
replication cohorts (P=0.01), and exhibited no association with the risk of lung squamous cell carcinoma 
(LSQ) or of small cell lung cancer (SCLC) in either cohort (Fig. 2a and Supplementary Table 5). Females 
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carrying L2307F showed an 8.05-fold (P=0.0001), 4.69-fold (P=0.004) and 6.10-fold (P=2.14x10-6) greater 
risk of LAD in the discovery, replication and meta-analysis, respectively (Fig. 2b and Supplementary 
Table 6). All the L2307F homozygotes, no matter what age, gender, and smoking status, developed LAD 
in this study (P=0.004) (Fig. 2c). Moreover, the association exhibited a dose-response relationship between 
the number of mutated alleles and the LAD risk in the discovery cohort (Ptrend=5.44x10-9). A more 
significant role for L2307F in LAD etiology than in LSQ or SCLC is reflected in the no observed mutational 
frequency in LSQ and SCLC in the replication cohort. These results suggested the association between 
rs56009889 and lung cancer risk was restricted to LAD, especially in women. Although previous studies 
have failed to demonstrate ATM-L2307F affects lung cancer risk, since ATM protein is responsible for 
repairing the broken DNA strands and maintaining the stability of genes17, not surprisingly there is 
variability in genetic effects on lung cancer risk by histology with subtype-specific associations at ATM-
L2307F. 
 
Interestingly, the ATM-L2307F was found in 4.43% (MAF=0.023) individuals from Israel, especially in 
7.34% (47/640) of Ashkenazi Jews, even though rs56009889 was almost monomorphic in other European 
countries (Supplementary Table 7). Concordant with such results is the finding that Ashkenazi Jews also 
had high prevalence of harmful BRCA founder mutations18. In addition, North Americans were observed 
to have a slightly higher prevalence for this specific harmful ATM-L2307F (MAF=0.002) than general 
Europeans. We therefore investigated if the association of rs56009889 and lung cancer risk was affected 
by country of origin. In both Israeli and North Americans, rs56009889 was significantly associated with 
the risk of lung cancer, of LAD in general and in women, respectively, in the discovery cohort. However, 
the association was substantially stronger and higher in the Israeli population than in North Americans (Fig. 
2d).  The ORs for LAD risk among L2307F carriers were 3.36 in North Americans (P=0.004) and 6.74 in 
the Israeli population (P=3.85x10-6).  The female carriage of L2307F conferred LAD risk with an OR of 
3.81 in North Americans (P=0.04) and 17.15 for the Israeli (P=0.006). There were no Israeli samples 
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available in the replication data. Our results by geographic populations validated the association and 
significance of L2307F for LAD, especially in women. 
 
rs150665432, a premature stop codon, is mapped within KIAA0930 (Fig. 1b) locating at 22q13.31 that is 
associated with 22q13 deletion syndrome and lung cancer risk19,20. Mutation in rs150665432 is responsible 
for Q4X and truncate the protein length from 409 to 3 amino acids21 (Supplementary Fig. 1b). Compared 
to non-carriers (G/G), Q4X carriers (A/G+A/A) had an increased lung cancer risk in both discovery 
(adjusted OR=2.59; P=1.15x10-18) and replication cohorts (adjusted OR=1.69; P=0.03) (Fig. 3a). 
Additionally, all Q4X homozygotes developed lung cancer (P=2.29x10-8) (Fig. 3b), and the number of 
mutated alleles showed a dose-response relationship with lung cancer risk (Ptrend=1.51x10-19) in the 
discovery cohort (Table 1). No homozygotes were found in the replication cohort. Stratification analysis 
showed that Q4X had a significant risk among females, males, smokers, non-smokers (Supplementary 
Table 8), and of LAD, LSQ and SCLC (Supplementary Table 9) in the discovery cohort and in the meta-
analysis.  In the replication, none of the strata reached significance, reflecting the small number of 
individuals with this uncommon variant in the subset analyses. Although the frequency of rs150665432 in 
controls varies non-significantly between geographic populations, ORs of the association between Q4X and 
lung cancer risk were higher in North American Countries (adjusted OR=4.19; P=3.27x10-16) than in 
European Countries (adjusted OR=1.65; P=0.0003, Supplementary Table 10). Although no previous 
study demonstrated Q4X affected the risk of any disease, the possible involvement of Q4X in the complex 
genetics of a severe congenital heart disease22 may indicate its pathogenicity. Our findings raise the 
possibility KIAA0930-Q4X may have a direct effect on lung cancer risk. 
 
We also investigated whether the mutations were associated with the onset age of lung cancer and found 
that mean onset age for female LAD cases harboring ATM-L2307F was later than that for cases among 
non-carriers with significance in the discovery cohort (69.37±10.71 vs 62.78±11.06, P=0.0007) and 
borderline significance because of small number of individuals in the replication cohort (68.74±10.49 vs 
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63.69±10.31, P=0.09, Supplementary Table 11 and Fig. 2e).  The difference of age for lung cancer in 
general and other strata was not validated in two cohorts. We also found significant differences of onset 
age between various genotypes was shown in cases among North Americans, but not among Israeli or in 
controls in the discovery data (Supplementary Table 12 and 13). A significant multiplicative interaction 
on the onset age was also found between rs56009889 and countries (P=0.01), and rs56009889 was 
associated with onset age adjusted for countries (P<0.0001) in the discovery cohort, supporting L2307F 
affected onset age of lung cancer. Although it is counter-intuitive that L2307F may be associated with late-
onset LAD in females because germline mutations are associated with early-onset cancers in general, 
concordant with our results was that TP53 germline mutations can be related to late-onset common 
cancers23 and that familial cancers can exists in cancers of advanced ages24. A possible explanation for our 
observations is that ATM previously is more active at elderly age25. No consistent variation in age by 
genotypes of rs150665432 was found overall or in subgroups (Supplementary Table 14).  
 
In order to verify the effect of the mutations on lung cancer risk, we also performed structure-based 
prediction to determine its functional significance. Using SNPeffect 4.026, we found that L2307F had a 2.2-
fold greater TANGO score, which defined protein aggregation based on the physics-chemical principles of 
β-sheet formation27, than the wildtype protein, suggesting L2307F contributed to protein aggregation. By 
applying PolyPhen-228, L2307F was categorized as being deleterious with a probability of 0.98 and a false 
discovery rate of 0.09, implying it damaged the stability and function of ATM protein29. Although it has 
not been biochemically characterized, Fathmm-XF30 labeled L2307F ascribed to pathogenic mutations31. 
Therefore, it is possible that L2307F could influence cancer risk. Q4X truncates KIAA0930 to 3 amino 
acids21 and therefore completely abolishes KIAA0930 protein and destroys its function.  
 
Because KIAA0930 is an uncharacterized protein32, we elucidated its role in lung cancer pathogenesis by 
investigating whether its expression was regulated during lung cancer development, as long as comparing 
its significance to ATM which is cancer suppressor protein. The surprise is that KIAA0930 was 
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significantly over-expressed in LAD (P=0.004) and LSQ (P=1.62x10-12) in TCGA database (Fig. 3c and 
3d), while ATM was up-regulated with a borderline significance in LAD and LSQ (Supplementary fig. 
2). Harvard expression data33 confirmed that KIAA0930 showed significant over-expression in lung cancer 
than in normal lung samples (P=0.0005), while ATM had different significance in exon-Level expression 
(P=0.01for exon 2 and P=0.15 exon 5) (Supplementary Table 15). Additionally, we observed KIAA0930 
expression was significantly upregulated in the majority of carcinomas, but not in other cancer types 
(Supplementary Table 16), meaning that KIAA0930 is a carcinoma-associated candidate gene, which was 
suggested by the data in The Human Protein Atlas showing that KIAA0930 expression significantly affect 
survival in patients with carcinomas34. 
 
In conclusion, this whole-exome study documents that among ~19,000 genes examined, ATM and 
KIAA0930 show the strongest evidence to be the candidate gene that were responsible for lung cancer 
etiology.  The most common germline mutation reported in the lung adenocarcinomas in the Cancer 
Genome Atlas were heterozygous mutations in ATM occurring in aggregate among 1.2% of cases35. 
However, the L2307F mutation was not identified, perhaps because of its rarity in many North American 
populations. The new cohorts, in which we investigated our mutations, had large sample sizes and have not 
been previously used to search for uncommon high-risk germline mutations, which improved our ability to 
identify novel germline mutations and genes contributing to lung cancer. Elements of our study design, 
such as validating results in two independent cohorts, analyzing the data by geographic populations, 
confirming the genotyping fidelity, comparing MAFs of the mutations in our cohorts to those in public 
sequencing datasets and investigating gene expression, ensure the reliability for our results. Notably the 
identification of the novel lung cancer related germline mutations and genes could greatly advance our 
understanding of lung cancer etiology. 
 
Online Methods 
Study subjects  
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The OncoArray consortium, which was used in the discovery phase, is a network created to increase 
understanding of the genetic architecture of common cancers.  The Dartmouth component of the 
Oncoarray consortium included GWAS data from 57,776 samples, obtained from 29 lung cancer studies 
across North America and Europe, as well as Asia36,37, along with additional samples from head and neck 
cancer patients that were included to improve genotype calling for rare variants. The OncoArray 
consortium participants who were lacking disease status (because they were not part of the lung cancer 
related studies), who were close relatives (second-degree relatives or closer) or who were duplicate 
individuals or other subjects, or who had a low call rate of genotype data, or who did not pass quality 
control, or who were non-European, were excluded from the current study. There were 5742 participants 
in the OncoArray consortium who had duplicate samples for the Affymetrix study that was used in the 
replication phase, and therefore these samples were also excluded from the analysis in the discovery 
phase. Finally, a total of 28,878 European-descent participants from 26 studies 37, including 15,851 lung 
cancer cases and 13,027 healthy controls, were included in the discovery cohort of the current case-
control study.  
 
The 26 studies in the current discovery cohort included the Alpha-Tocopherol Beta-Carotene Cancer 
Prevention Study (ATBC), Canadian screening study (Canada), Cancer de Pulmon en Asturias 
(CAPUA),Copenhagen lung cancer study (COPENHAGEN), Environment and Genetics in Lung Cancer 
Study Etiology (EAGLE), The Carotene and Retinol Efficacy Trial (FHCRC), Liverpool Lung Cancer 
Project (FIELD), German lung cancer study (GERMANY), Harvard Lung Cancer Study (HSPH), The 
IARC L2 Study  (IARC), Israel study (ISRAEL), The Kentucky Lung Cancer Research (KENTUCKY), 
MD Anderson Cancer Center Study (MDACC), The Malmö Diet and Cancer Study (MDCS), Multiethnic 
Cohort Study (MEC), New England Lung Cancer Study (NELCS), new samples from Harvard 
(NEWSAMPLE-600), The Nijmegen Lung Cancer Study (NIJMEGEN), Norway Lung Cancer Study 
(NORWAY), Northern Sweden Health and Disease Study (NSHDC), The Prostate, Lung, Colorectal and 
Ovarian Cancer Screening Trial (PLCO), RESOLUCENT study (RESOLUCENT), Tampa Lung Cancer 
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Study (TAMPA), Total Lung Cancer: Molecular Epidemiology of Lung Cancer Survival (TLC), The 
Mount-Sinai Hospital-Princess Margaret Study (TORONTO), The Vanderbilt Lung Cancer Study 
(VANDERBILT). Among the 26 studies, 13 studies, including ATBC, CAPUA, COPENHAGEN, 
EAGLE, FIELD, IARC, MDCS, NIJMEGEN, NORWAY, ISRAEL, NSHDC, GERMANY and 
RESOLUCENT, obtained samples from Europe. Another 13 studies, including CANADA, FHCRC, 
HSPH, KENTUCKY, MDACC, MEC, NELCS, PLCO, TAMPA, TLC, TORONTO, and 
VANDERBILT, recruited subjects from North America. 
 
We used Affymetrix Axiome array study 38 from the Transdisciplinary Research in Cancer of the Lung 
consortium in the replication phase. The Affymetrix Axiome array study was a large pooled sample, 
assembled from 10 independent case-control studies, including Mount-Sinai Hospital-Princess Margaret 
(MSH-PMH), Multiethnic Cohort, Liverpool Lung Project, Nurses’ Health Study and National Physicians 
Health Study, the European Prospective Investigation into Cancer and Nutrition (EPIC) Lung, the 
Prostate, Lung and Ovarian Cancer Screening Trial, Carotene and Retinol Efficacy Trial, Russian Multi-
Cancer Case-Control Study, Melbourne Collaborative Cohort Study and Harvard Lung Cancer Study 38.  
Of the 12651 subjects in the Affymetrix Axiome array study, the participants who were lacking disease 
status, or who were non-European, or whose samples did not pass quality control, were excluded. Finally, 
the replication cohort of the current case-control study comprised a total of 10,268 European-descent 
participants, including 4,916 lung cancer cases and 5,352 healthy controls. 
 
All studies were reviewed and approved by institutional ethics review committees at the involved 
institutions. 
 
Genotyping  
A novel technology developed by Illumina to facilitate efficient genotyping was used to genotype 
OncoArray samples 37,39. The lists of genotyped SNPs were designed and generated to include about 
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230,00 SNPs in a GWAS backbone; a dense set of SNPs within genes that were associated with 
pharmacogenetic traits relevant to cancer; SNPs within a susceptibility regions for common cancer types 
(breast, prostate, colon, ovarian or lung); within 1 Mb of known variants relevant to cancer-associated 
traits, risk variants from epigenetic datasets; variants in genome-wide regulatory profiling data for lung, 
breast, prostate and ovarian cancers. This process resulted in a total of 568,712 SNPs submitted to 
Illumina for manufacturing. Finally, 533,631 variants passed quality control procedures and were 
included as valid markers39, of which 105,736 variants were rare variants. Genotyping  395,745 SNPs 
from samples of the Affymetrix study was performed using a custom Affymetrix Axiom Array 
(Affymetrix, Santa Clara, CA, USA), which contains a comprehensive panel of key GWAS markers, rare 
and low-frequency variants and indels 38. 
 
Statistical analyses for demographic characteristics  
To discover the driver germline mutations with high effect on lung cancer risk, we performed association 
analyses for all the mutations within the exome having Minor Allele Frequencies (MAF) less than 0.01. 
 
Descriptive statistical analyses were conducted to characterize the study population of lung cancer cases 
and controls in both discovery and replication cohorts. The difference between cases and controls in the 
distribution of age at diagnosis, gender and smoking status were evaluated using the χ2 test. Statistical 
analyses were performed with Statistical Analysis System software (Version 9.3). Principal component 
analysis was performed based on GWAS data with the EIGENSTRAT program for both discovery and 
replication cohorts, respectively. To calculate these principal components, we analyzed GWAS data after 
excluding the sex chromosomes, variants with MAF less than 0.05 and after sampling SNPs that were 
uncorrelated with each other. 
 
Genotyping concordance between OncoArray genotyping and Affymetrix genotyping 
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We confirmed the genotyping fidelity of the selected germline mutations in the OncoArray platform and 
the Affymetrix platform, respectively, by considering the concordance of these genotypes between the 2 
platforms. A total of 5,742 subjects in the OncoArray consortium were duplicate individuals in the 
Affymetrix data. Even though the 5,742 subjects were excluded in the discovery cohort and included in 
the replication cohort, we calculated the concordance of genotyping between the OncoArray consortium 
and the Affymetrix study for the selected germline variants in the 5,742 individuals whose genotyping 
results were available for both platforms.  
 
The concordance rate was based on the agreement between OncoArray genotyping and Affymetrix 
genotyping, and we considered the general concordance and also concordance between the rare alleles 
only39. Supplementary Note Table 1 below describes the genotype frequencies in different situations of 
agreement between OncoArray genotyping and Affymetrix genotyping.  
 
Supplementary Note Table 1. Genotype frequencies based on the agreement between OncoArray 
genotyping and Affymetrix genotyping. 
  OncoArray Genotyping 
Affymetrix Genotyping major/major major/minor minor/minor 
major/major a b c 
major/minor d e f 
minor/minor g h i 
 
The general concordance rate was estimated using the genotype frequencies, which were in agreement 
between OncoArray genotyping and Affymetrix genotyping, incorporating all genotype frequencies (n). 
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The concordance of rare alleles was estimated using the genotype frequencies of the minor/minor and 
major/minor, which were in agreement between Oncoarray genotyping and Affymetrix genotyping, 
incorporating all genotype frequencies other than the genotype frequency of major/major. 
 
 
Validation of the reliability of genotyping data  
In order to further validate the reliability of genotyping data, we compared the MAFs of the selected 
germline mutations in unaffected individuals of the discovery and the replication cohort, respectively, to 
those in public sequencing projects or datasets including the Exome Aggregation Consortium (ExAC) 12, 
the NHLBI GO Exome Sequencing Project (GO-ESP) 40 and the Trans-Omics for Precision Medicine 
(TOPMed) Program. ExAC is a released public exome sequencing dataset with variations on 60,706 
unrelated individuals that included 33,370 individuals from a non-Finnish European population and 3,307 
Finnish European population. GO-ESP is an exome sequencing project that included European American 
and African American participants 40. TOPMed sequenced the DNA of people from diverse ethnic 
backgrounds, with  50% being of European descent and 30% of African descent 41. 
 
Association analysis  
Case-control association tests for genotyped data were conducted using 1-degree-of-freedom Cochran-
Mantel-Haenszel tests with the application of PLINK version 1.9 to discover the germline mutations with 
large effects on lung cancer risk. We estimated the association between the risk of lung cancer and the 
selected germline mutations by computing the odds ratios (ORs) and 95% confidence intervals (CIs) in 
univariate and multivariate logistic regression analyses in both cohorts. In the multivariate logistic 
regression model, OR and 95% CI were adjusted by age, gender, smoking status (never and ever) and 
significant principal components. We further stratified the association of the selected germline mutations 
and lung cancer risk by gender and smoking status. We also estimated the association between the 
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selected SNP variants and the risk of lung adenocarcinoma, lung squamous cell carcinoma or small cell 
lung cancer, respectively, in univariate and multivariate logistic regression analyses.  
 
We further stratified the association in the discovery cohort by geographic populations in univariate and 
multivariate logistic regression analyses. Based on the MAF of rs56009889 and the location of the study 
sites in the discovery cohort, we categorized all the studies to 3 subgroups, including Israeli among which 
rs56009889 had the highest MAF, population in other European countries, and North Americans. Since 
the frequency of rs150665432 in controls varies non-significantly between geographic populations, we 
categorized all the studies to 2 subgroups, including population in European countries and North 
American countries, to calculate the associations of rs150665432 and lung cancer risk in different 
geographic populations. 
 
Statistical analyses were performed with SAS 9.3 in both discovery and replication phase; a p-value of 
less than 0.05 was considered to be significant. 
 
Meta-analysis 
Case-control association results of both cohorts from PLINK version 1.9 and the results of multivariate 
logistic regression analysis in both cohorts were performed using meta-analyses with the application of R 
package ‘meta’ (http://www.imbi.uni-freiburg.de/lehre/lehrbuecher/meta-analysis-with-r) that combined 
test statistics and standard errors across studies. A fixed effect model was used to combine the studies in 
meta-analysis.  
 
Analysis of the differences in age 
Student t-test was used to evaluate the differences in age at onset of lung cancer between different 
genotypes of the selected germline mutations in cases. We then evaluated the differences in age at onset 
with stratified by gender, smoking status and histology of lung cancer. In addition, we stratified the 
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differences in age at onset of lung cancer by the continental origins. For rs56009889, the types of 
countries were categorized as follows: (a) Israel, which had the highest MAF, (b) Countries with 
youngers only, including studies in Europe for which selection was based on early age of onset that 
included 2 substudies from GERMANY and RESOLUCENT from the UK (mean age = 44.83 years for 
GERMANY and 54.74 years for RESOLUCENT), (c) Other European Countries or (d) North American 
countries which included the studies located in North America. These categories were formulated based 
on locations and MAFs of the selected variants, as well as on the age limitation of recruitment. 
 
To support the reliability of the differences in age at onset of lung cancer between different genotypes of 
rs56009889 in cases, we then compared the age at study registration between different genotypes of 
rs56009889 in controls. 
 
To investigate whether or not rs56009889 was associated with onset age, we used a multivariable logistic 
regression model adjusted for the types of countries. To explore the effect of the interaction between the 
genotypes of the selected mutations and the types of countries on the onset age of lung cancer, we built a 
multivariate logistic regression model with adjustment for the types of countries and the genotypes of the 
selected mutations. In both models, age at onset of lung cancer in cases was categorized as follows: (a) 65 
years of age or older, or (b) <65 years of age.  
 
Structure-based prediction 
Structure-based prediction is a determinant of the functional significance of missense variants42. With 
using SNPeffect 4.026, we explored TANGO43 that is a statistical mechanics algorithm to predict protein 
aggregation based on the physics-chemical principles of β-sheet formation27. PolyPhen-228 was applied to 
predict the functional effects of the germline mutations. We used Fathmm-XF30 to perform accurate 
prediction of the functional consequences of the mutations with applying machine learning method. 
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Gene Expression Data 
The Cancer Genome Atlas (TCGA, https://tcgadata.nci.nih.gov/tcga/) level 3 RNA-seq data and clinical 
patient data related to 19 cancer types, composing of  lung adenocarcinoma (LUAD) that included 515 
tumor samples and 59 normal samples, lung squamous cell carcinoma (LUSC) that included 503 tumor 
samples and 52 normal samples, bladder urothelial carcinoma (BLCA), breast invasive carcinoma 
(BRCA),cervical squamous cell carcinoma (CESC),cholangiocarcinoma (CHOL),colon adenocarcinoma 
(COAD), esophageal carcinoma (ESCA),glioblastoma multiforme (GBM), head and neck squamous cell 
carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma 
(KIRP), liver hepatocellular carcinoma (LIHC),pancreatic adenocarcinoma (PAAD), prostate 
adenocarcinoma (PRAD), rectal adenocarcinoma (READ), Sarcoma, Thymoma, thyroid carcinoma 
(THCA), were used to investigate whether or not the expression of ATM or KIAA0930 were associated 
with the primary cancer. A total of 7570 samples, including 6930 tumor samples and 640 normal samples, 
were consisted in the analysis. portal was employed for estimating  The significance of difference in gene 
expression levels between tumor and normal samples was estimated by comparing generating Transcripts 
per million (TPM) expression values with employing UALCAN to perform t-test44. 
 
Harvard lung expression data33 included the mRNA expression values for 12,600 genes that was rescaled 
and normalized from the raw expression data by a rank-invariant scaling method, in order to removing the 
batch differences. A total of 203 samples, including 127 lung adenocarcinomas, 21 lung squamous cell 
carcinomas, 20 lung carcinoids, 6 small cell lung cancer and 17 normal lung specimens, were consisted in 
the study and performed with microarray analysis. Of the 12,600 genes, both ATM and KIAA0930 were 
included. Additionally, exon 2 and 5 of ATM were analyzed because isoform changes without 
corresponding whole gene expression changes were showed to be associated with tumor phenotype45. We 
used t-test to evaluate the differences in gene expression levels of ATM exon 2 and 5 and KIAA0930, 
respectively, between lung cancer and normal lung samples, in general and within each histologic type. 
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Data availability 
The data that support the findings of this study are available. The access numbers are “phs001273” for 
Oncoarray study and “phs000876.v2.p1.” for Affymetrix study in dbGAP. The Cancer Genome Atlas 
(TCGA, https://tcgadata.nci.nih.gov/tcga/) level 3 RNA-seq data are publicly available. Harvard lung 
cancer mRNA expression data were available at www.pnas.org. 
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Fig. 1: Regional lung cancer association plots for the ATM and KIAA0930 risk loci. a, ATM region 
for lung cancer risk. rs56009889, localizing to chromosome 11 and mapping within ATM, is not in 
linkage disequilibrium (LD) with any SNPs that have been identified before; b, KIAA0930 region for lung 
cancer risk. rs150665432 localizes to chromosome 22 and maps within uncharacterized KIAA0930, which 
is not in LD with any SNPs that have been identified before. For each plot, −log10 P values (y-axis) of the 
SNPs are shown according to their chromosomal positions (x-axis). The top genotyped SNP in each 
analysis is labeled by its rs number. The color intensity of each symbol reflects the extent of LD with the 
top lung cancer-associated SNP in the discovery data: blue (r2=0) through to red (r2=1.0). Physical 
positions are based on NCBI build 37 of the human genome. The relative positions of genes are also 
shown.  
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Fig. 2: ATM rs56009889 association with lung cancer risk by histological subtypes, sex, and age of 
onset. a, Compared to non-carriers, L2307F carriers had an increased risk of lung cancer  with ORs being 
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4.19 in the discovery cohort (P=3.56x10-7) and 1.31 in the replication cohort (P=0.45). In females, 
L2307F carriers had a lung cancer risk with ORs being 7.76 in the discovery cohort (P=0.0002) and 3.22 
in the replication cohort (P=0.03). In males, L2307F carriers had a lung cancer risk with ORs being 3.34 
in the discovery cohort (P=0.0006) and 0.40 in the replication cohort (P=0.13). L2307F carriers had a 
significant 5.2-fold increased risk for LAD in the discovery cohort (P=6.47x10-9) and a 2.5-fold increased 
risk in the replication cohort (P=0.002). No associations of L2307F with the risk of LSQ or SCLC were 
observed. b, Stratified analyses of the association between rs56009889 and LAD. Females who carried 
L2307F had a >8-fold greater risk of LAD in the discovery cohort (P=0.0001) and a 4.7-fold risk of LAD 
in the replication cohort (P=0.004). In never smokers, L2307F exhibited a >6-fold greater risk of LAD in 
the discovery cohort, but we did not confirm this finding in the replication cohort. Never smoking females 
who harbored L2307F had a 7-fold greater risk of LAD in the discovery cohort (P=0.01) and a 3.8-fold 
risk of LAD in the replication cohort (P=0.07). c, Distribution of L2307F homozygotes. All the 
homozygotes of L2307F in the discovery cohort, no matter what age, gender, and smoking status, 
developed LAD in the discovery cohort (P=0.004). No homozygotes were found in the replication cohort. 
d, Higher ORs of association between rs56009889 and the risk of lung cancer, of LAD in overall and in 
females were found in Israeli than in North Americas. All of the associations have reached significant. e, 
rs56009889 affects the age of onset. In the discovery cohort, the mean age of onset for lung cancer cases 
carrying L2307F was significantly higher than cases of non-carriers. This was observed for overall lung 
cancer, females, males, smokers, LAD and females with LAD. In the replication cohort, a borderline 
significant difference in the age of onset was observed only in females with LAD and non-smoker with 
LAD though the sample size is small. No carrier of the T allele developed LSQ and SCLC in the 
replication cohort. 
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Fig. 3: KIAA0930 rs150665432 associated with lung cancer risk. a, Stratified analyses of the 
association between Q4X and lung cancer risk. Compared to non-carriers, Q4X carriers had a 
significantly increased lung cancer risk with ORs being 2.59 in the discovery (P=1.15x10-18) and 1.69 in 
the replication cohort (P=0.03). Stratified analysis showed that Q4X carriers had an increased risk for 
lung cancer among females, males, smokers and non-smokers. We also found Q4X were associated with 
an enhanced risk of LAD, of SCLC, and of LSQ in both discovery and replication cohorts. The risk 
26 
 
associated with rs150665432 appeared to have no difference between males and females, or between 
smokers and non-smokers, or for various histology types. b, Distribution of Q4X homozygotes. In the 
discovery cohort, all homozygotes of the mutated allele in rs150665432 were developed to lung cancer in 
the discovery cohort (P=2.29x10-8), no matter what age, gender and smoking status. No Q4X 
homozygotes were found in the replication cohort. c, Box-whisker plot of KIAA0930 expression in LAD. 
KIAA0930 is significantly over-expressed in LAD than in normal lung tissue. d, Box-whisker plot of 
KIAA0930 expression in LSQ. KIAA0930 is significantly over-expressed in LSQ than in normal lung 
tissue.
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Table 1. Associations for LAD with ATM-L2307F (rs56009889) and for lung cancer with KIAA0930-Q4X(rs150665432)   
        Discovery Cohort   Replication Cohort           
    No.  Adjusteda    No.  Adjusteda   Meta-analysis# 
Outcome Population Gene Genotype Control Case    OR (95%CI) P   Control Case    OR (95%CI) P   OR (95% CI) P 
lung 
cancer All ATM CC 13005 15767  1     5331 4891  1         
   TC 18 77  3.79 2.2 6.6 2.57E-06  15 19  1.31 0.65 2.65 0.45  2.52 1.63 3.91 3.2E-05 
   TT 0 5  Inf 0.8 Inf 0.068*  0 0  - - - -  - - - - 
   TC+TT 18 82  4.19 2.4 7.3 3.56E-07  15 19  1.31 0.65 2.65 0.45  2.7 1.75 4.16 7.8E-06 
   Trend       2.45E-07             - 
lung 
cancer Female ATM CC 5096 5777  1     2475 2203  1         
   TC 4 41  7.67 2.6 22 0.0002  5 15  3.22 1.12 9.21 0.03  4.94 2.34 10.5 2.9E-05 
   TT 0 1  Inf 0 Inf 0.49*  0 0  - - - -  - - - - 
   TC+TT 4 42  7.76 2.7 22 0.0002  5 15  3.22 1.12 9.21 0.03  4.97 2.35 10.5 2.7E-05 
   Trend       0.0002             - 
LAD All ATM CC 13005 6267  1     5331 2139  1         
   TC 18 61  4.68 2.7 8.2 7.92E-08  15 18  2.48 1.22 5.04 0.01  3.66 2.36 5.69 7.9E-09 
   TT 0 5  Inf 1.9 Inf 0.004*  0 0  - - - -  - - - - 
   TC+TT 18 66  5.23 3 9.2 6.47E-09  15 18  2.48 1.22 5.04 0.01  3.93 2.53 6.1 1E-09 
   Trend       5.44E-09             - 
LAD Female ATM CC 5096 2923  1     2475 1186  1         
   TC 4 32  7.91 2.7 23 0.0002  5 14  4.69 1.65 13.4 0.004  6.05 2.86 12.8 2.5E-06 
   TT 0 1  Inf 0 Inf 0.36*  0 0  - - - -  - - - - 
   TC+TT 4 33  8.05 2.8 23 0.0001  5 14  4.69 1.65 13.4 0.004  6.1 2.89 12.9 2.1E-06 
   Trend       0.0001              - 
lung 
cancer All KIAA0930 GG 12642 14814  1     5308 4861  1         
   AG 126 355  2.41 2 3 7.83E-16  32 47  1.69 1.05 2.7 0.03  2.27 1.87 2.75 1.9E-16 
   AA 0 29   Inf 6.3 Inf 2.29E-08*  0 0  - - - -  - - - - 
   AG+AA 126 384  2.59 2.1 3.2 1.15E-18  32 47  1.69 1.05 2.7 0.03  2.41 1.99 2.92 3.9E-19 
     Trend             1.51E-19                         - 
                   
aAdjusted for age at diagnosis/interview, gender, smoking status and PCs.            
#Fixed-effects meta-analysis adjusted for age at diagnosis/interview, gender, smoking status and PCs.        
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*Values generated from Fisher's Exact Test.                
   
 
 
